Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanette Leusen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Blood|March 20, 2025
Complementing CD20 antibodies' effector functionsJeanette Leusen, Thomas Valerius
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 4, 2015
Meeting report on immunoreceptors 2014Toine Ten Broeke, Annemiek van Spriel, Peter Sun, et al.
Antibodies (Basel, Switzerland)|December 18, 2020
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic AgentsGeert van Tetering, Mitchell Evers, Chilam Chan, et al.
Mabs|March 11, 2021
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn <i>in vitro</i> and <i>in vivo</i>Simone Mester, Mitchell Evers, Saskia Meyer, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 14, 2022
Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®Alexander H Staudacher, Vasilios Liapis, Nicole L Wittwer, et al.
Journal for Immunotherapy of Cancer|May 23, 2024
Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockadeChilam Chan, Marjolein Stip, Maaike Nederend, et al.
Molecular Therapy Oncolytics|March 13, 2023
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenovirusesFiras Hamdan, Michaela Feodoroff, Salvatore Russo, et al.
Journal for Immunotherapy of Cancer|October 30, 2021
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastomaMitchell Evers, Marjolein Stip, Kaylee Keller, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptorsSara Feola, Firas Hamdan, Salvatore Russo, et al.
Oncoimmunology|February 7, 2022
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposureTassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Blood|March 20, 2025
Complementing CD20 antibodies' effector functionsJeanette Leusen, Thomas Valerius
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 4, 2015
Meeting report on immunoreceptors 2014Toine Ten Broeke, Annemiek van Spriel, Peter Sun, et al.
Antibodies (Basel, Switzerland)|December 18, 2020
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic AgentsGeert van Tetering, Mitchell Evers, Chilam Chan, et al.
Mabs|March 11, 2021
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn <i>in vitro</i> and <i>in vivo</i>Simone Mester, Mitchell Evers, Saskia Meyer, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 14, 2022
Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®Alexander H Staudacher, Vasilios Liapis, Nicole L Wittwer, et al.
Journal for Immunotherapy of Cancer|May 23, 2024
Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockadeChilam Chan, Marjolein Stip, Maaike Nederend, et al.
Molecular Therapy Oncolytics|March 13, 2023
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenovirusesFiras Hamdan, Michaela Feodoroff, Salvatore Russo, et al.
Journal for Immunotherapy of Cancer|October 30, 2021
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastomaMitchell Evers, Marjolein Stip, Kaylee Keller, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptorsSara Feola, Firas Hamdan, Salvatore Russo, et al.
Oncoimmunology|February 7, 2022
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposureTassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, et al.
Pageof 2